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Abstract
Background: Ataxia telangiectasia-mutated (ATM) gene contributes to repair damaged DNA and to regulate cell
cycle; therefore, ATM variants seem to increase breast cancer risk; however, the results are controversial. So we
conducted a systematic review and meta-analysis to clarify the pooled association between various ATM variants
and the risk of breast cancer.
Methods: The relevant studies were searched through Scopus, Web of Science, PubMed and Cochrane. Stratified
and subgroup analyses were performed to explore heterogeneity between studies and assess effects of study
quality. The pooled estimates logarithm with standard error logarithm of odds ratio and relative risk with
confidence interval were calculated.
Results: This study revealed that there is association between ATM variants and the risk of breast cancer; according
to the seven adjusted case-control studies, OR of this association was estimated as 1.67 (95%CI: 0.73–3.82),
according to nine unadjusted case-control studies, the crude OR was 2.27 (95% CI: 1.17–4.40) and according to two
cohorts, the RR was estimated as 1.68 (95% CI: 1.17–2.40).
Conclusions: The ATM variants are associated with an increased risk of breast cancer that ATM V2424G mutation is
detected as the most predisposing factor while ATM D1853V, L546V, and S707P variants have the least predictive
ability.
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Background
Breast Cancer is the most common cancer in women
and causes the highest mortality rate in developed and
developing countries [1]. Annually, 1.67 million women
become infected with this type of cancer and have 522,000
mortality rate each year [2]. According to the World
Health Organization (WHO) report, 1 out of 9 women in
the world suffers from this type of cancer during
their life. The Clinical manifestations of breast cancer
are very different in patients and these various mani-
festations largely depend on the type of genetic muta-
tion. Accurate diagnosis of cancer based on the type
of mutation is very helpful for deciding on the treat-
ment and follow up of patients [3].
During the last decade, BRCA1 and BRCA2 mutations
(BRCA1/2) have been screened for hereditary breast
cancer and results showed that mutations in BRCA1/2
account for 5% of hereditary breast cancer [1, 4]. Be-
sides, a recent large population study showed that other
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pathogenic gene variants, including ataxia telangiectasia-
mutated (ATM) variants, were frequently detected
among breast cancer women [5, 6]. The ATM gene is lo-
cated on 11q22–23 chromosome and consists of 66
exons that encode a 350 kDa protein kinase enzyme [7,
8]. This gene plays an important role in regulating the
cell cycle and repairing the DNA damage induced by
ionizing radiation. Exposure to ionizing radiation, even
in very low doses, can trigger a break down significant
amount of cellular inactive homodimer ATM to active
monomers [9, 10]. The activated ATM phosphorylates a
number of its downstream targets such as p53, chek2
and BRCA1 which stops the cell cycle, repairs DNA or
apoptosis, so a mutation in either of these genes causes
insufficient cellular repair and ultimately increases the
incidence of cancer [9, 11].
Mutations in the ATM gene caused Ataxia Telangi-
ectasia (A-T), an autosomal recessive syndrome that
patients have symptoms such as ionizing radiation sensi-
tivity, cerebellar neurodegeneration immunodeficiency
and markedly increased risk of cancers like breast cancer
[12–14]. The incidence of breast cancer among female
relatives of A-T families was increased [15–18]. Also,
Epidemiologic studies have estimated that obligate het-
erozygous carriers of an ATM mutation have a 2–5-fold
increased risk of breast cancer [13, 19, 20]. In addition,
it is reported that breast cancer patients with mutated
ATM variants who undergo radiotherapy developed
their second tumor sooner than the group with no treat-
ment of radiation and no ATM mutations [21].
Since the detection of the ATM gene in 1995, several
studies have been conducted on the association of muta-
tions of this gene and the risk of breast cancer which
had contradictory results and to our knowledge, no sys-
tematic study was conducted to examine the association
between different variants of ATM and breast cancer.
Therefore, the current study aims to clarify the pooled
relationship between ATM variants and breast cancer.
Main text
Methods
All methods used in this meta-analysis were according to
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement (PRISMA) [22]. The protocol of
this study had been registered in the International Pro-
spective Register of Systematic Reviews (PROSPERO),
under the registration number of CRD42018114394.
Search terms and complex search syntax
To evaluate the relationship between breast cancer and
Ataxia Telangiectasia Mutated Proteins, four English da-
tabases including Scopus, Web of Science (EMBASE),
PubMed, and Cochrane were browsed up to 20 October
2018. In current study “breast carcinoma”, “breast
tumor”, “breast neoplasm”, “breast neoplasms”, “breast
cancer”,” breast cancers”, “breast tumors”, “ataxia telangi-
ectasia mutated”, “ataxia telangiectasia mutated proteins”,
“ATM”,” mutation”, “mutations”, “variant”, and “variants”
keywords were searched in the mentioned databases. Be-
cause of avoiding missing any papers, the reference list of
primary articles was screened manually. The primary
search results were reviewed, and some articles were elim-
inated after reviewing their title and abstract. Inclusion
and exclusion criteria were set by 2 researchers separately
(YM, MM).
Eligibility criteria
Articles were selected using the following criteria: (1) assess-
ment of the association between ATM variants and breast
cancer risk; (2) studies with full text articles; (3) case–control
and cohort studies; (4) sufficient data for estimating an odds
ratio (OR) with 95% confidence interval (CI).
Screening and data extraction
Full texts of each article were sensibly assessed by two
independent reviewers (ES and MM) and any probable
disagreements with these reviewers were resolved by
consultation with another author (YM) to settle the ar-
gument, and a concluding deduction was applied. The
following data were collected from each study: first au-
thor’s name, publication date, type of study, country,
study population, age, sample size, type of variant, meas-
urement of association and controlled variables.
Quality assessment and risk of Bias
The qualities of all studies were assessed by Modified
Newcastle-Ottawa Scale for Case Control studies [23].
This checklist was completed by two researchers (ES and
MM). The quality of studies was judged based on such as-
pects as selection, comparability and outcome. Scores
ranged from 0 stars (worst case) to 9 stars (best case).
Studies with a score of 0–4 were categorized as low qual-
ity, 5–7 as moderate, and more than 7 as high qualities.
Statistical analysis
Association between the ATM and breast cancer risk
was analyzed by pooling odds ratio (ORs) and risk ratio
(RR) with 95% confidence interval (CIs) using STATA
metan module. DerSimonian and Laird method were
used to compute the pooled estimate of odds ratio (OR)
and risk ratio (RR) with a confidence interval (CI 95%)
using random models [24]. Because the test for hetero-
geneity was statistically significant in some analyses, the
random effects models were used to estimate OR and
RR. In the fixed effects model approach, we used two
popular methods, which included the inverse variance-
weighted average method and the weighted sum of the z-
scores method. Although previous studies have shown
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that the two methods perform similarly, their characteris-
tics and their relationship have not been thoroughly inves-
tigated. Therefore, in present meta-analysis we used the
inverse variance-weighted model [25, 26]. In this study, w
Cochran’s Q test and I square statistic was used to evalu-
ate statistical heterogeneity between studies [27]. In
addition, a meta-regression and subgroup analysis were
performed to assess the source of heterogeneity between
studies. Moreover, publication bias was assessed by funnel
plot and Egger test [28, 29]. Statistical analysis was per-
formed using STATA 14.0 (Stata Corp, College Station,
TX, USA) and statistical significance was set at p < 0.05.
Results
Study characteristics
The first step of search in electronic databases yielded
397 publications. In the final step, after removing the
duplicates, reviewing by title, abstract and full text and
considering the inclusion and exclusion criteria, 18 stud-
ies were selected for the meta-analysis of the pooled as-
sociation between ATM and the risk of breast cancer
(Fig. 1). The characteristics of each study included in the
current meta-analysis are reported in Tables 1 and 2.
Association between ATM and breast Cancer in case
control studies
Adjusted case-control studies
The pooled estimate odds ratio after synthesis results of
7 Adjusted case control studies shows that the associ-
ation between ATM and risk of breast cancer was 1.67
(95% CI: 0.73–3.82; I square: 90.85%; PI square: 0.0001).
The range of OR between these studies was 0.2 to 11.60
(Fig. 2). The results of Egger’s test showed there isn’t a
publication bias in the association between ATM and
Fig. 1 PRISMA chart outlining the literature search
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risk of breast cancer (Coefficient = 2.08; P = 0.193; % 95
CI: − 0.56 – 3.16).
The results of subgroup analysis show that the highest
association between ATM variants and the risk of breast
cancer belongs to the Asian population with an odds ra-
tio of 4.21 (95%CI: 0.78–22.88; I square: 89.5%; PI square:
0.0001) while the lowest odds ratio was among the Euro-
pean population that was equal to 1.24 (95% CI: 0.94–
1.64; I square: 18.5%; PI square: 0.297). This suggests that
ATM variants have a greater impact on the risk of breast
cancer in the Asian population than in the European
and American populations (Table 3).
The results based on homo/heterozygosity status of
variants show that heterozygous variants had increased
the risk of breast cancer with a factor of 1.98 (95% CI
1.22–3.19; I square: 80%; PI square: 0.0001). Also there is
an association between homozygous variants and the
risk of breast cancer with an odds ratio (OR) of 1.63
(95% CI: 1.20–2.22; I square: 0.00%; PI square: 0.929).
Meanwhile, the lowest OR belonged to homo or hetero-
zygous which was equal to 1.22 (95% CI: 1.01–1.46; I
square: 0.00%; PI square: 0.433). This statistical analysis
indicates that heterozygous ATM variants are the most
associated with breast cancer incidence (Table 3).
In addition, results of subgroup analysis based on type
of variants show that the V2424G variant (c.7271 T > G)
is the most associated with breast cancer incidence (OR:
8.94; %95 CI: 4.28–18.67; I square = 0.00%; PI square =
0.789) and D1853V has the least impact on breast cancer
incidence (OR: 0.43; 95% CI: 0.09–2.07; 0.031; I square:
78.6%; PI square: 0.789) (Table 3).
Unadjusted case-control studies
From the 9 unadjusted case control studies, the associ-
ation between ATM variants and the breast cancer risk
ranged between 0.37 and 12.70. The pooled estimate of
crude odds ratio between ATM and risk of breast cancer
was 2.27 (95% CI: 1.17–4.40; I square: 74.56%; PI square:
0.0001) (Fig. 3). The results of Egger’s test showed no
publication bias in the association between ATM and
risk of breast cancer in unadjusted case control studies
(Coefficient: 0.398; P: 0.193; % 95 CI: − 0.21 – 1.00).
Subgroup analysis based on continent shows that
ATM variants have a greater impact on breast cancer in-
cidence in the Asian population than in the European
and American populations (Table 3). In addition, the
heterozygote ATM variants increased the risk of breast
cancer 1.31 times (95% CI: 1.05–1.64; I Square: 83.0%; PI
square: 0.0001) (Table 3).
Also, the evaluation of the effect of different variants
of ATM Gene on the incidence of breast cancer shows
that c.7271 T > G has the highest association with an OR
of 27.97 (95% CI: 5.01–35.07; I Square: 62.0%; PI square:
0.105) and L546V has the lowest association with an OR
of 0.37 (95% CI 0.19–0.73; 0.032; I Square:58.9; PI square:
0.105) (Table 3).
Association between ATM and breast Cancer in cohort
studies
Cohort studies
The results of two cohort studies showed a risk ratio
(RR) range of 0.6 to 6.10. The pooled risk ratio between
ATM variants and risk of breast cancer was 1.68 (95%
CI: 1.17–2.40; 0.032; I square: 62.1%; PI square: 0.105).
Discussion
ATM gene has been recognized in recent years as a low
penetrance breast cancer gene, which is a research goal
for many studies [31]. Based on the mentioned keywords
18 articles were evaluated and different variants of this
gene in three continents of Asia, America and Africa
were analyzed. Qualitative assessment of articles was
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performed by NOS criteria and the results showed that
all articles are of medium to high quality, so they met
the criteria for entering meta-analysis. The results of the
current study indicate that ATM missense variants in-
crease the incidence of breast cancer and people who
carry these variants have an increased risk of developing
breast cancer.
In the study by Easton DF et al. [32] in 2015, it is re-
ported that relatives of A-T patients encounter breast
cancer with a relative risk of 2.8 (90%CI: 2.2–3.7; P <
0.0001) [32]. Another study by van Os NJH et al. [33] in
2016 demonstrated that all women with pathogenic
ATM variants developed breast cancer with a relative
risk of 3.04 (90%CI: 2.06–4.48; P < 0.0001). Another
meta-analysis of 19 studies by Marabelli M et al. [34] in
2016 reported that the women who were the carriers of
ATM variants have a breast cancer relative risk of 6.02
(90%CI: 4.58–7.42) by the age of 50 years old and 32.83
(90%CI: 24.55–40.43) by the age of 80 years old [34]. As
the same as our findings, all these studies emphasized
that there is a strong association between ATM variants
and the risk of breast cancer development.
Of the 29 different variants examined in the current
study, V2424G (c.7271 T > G) missense variant had the
highest association with breast cancer incidence in dif-
ferent subgroups of adjusted case control, non-adjusted
case control and cohort studies. Although this associ-
ation varied across the three subgroups analyses, all re-
vealed that V2424G missense variant was strongly
accompanied by an increased risk of breast cancer. Bern-
stein JL et al. [9] in 2006 reported that women who were
carriers with V2424G missense variant had developed
breast cancer by the age of 70 years old with a cumula-
tive risk of 52% (95% CI = 28–80%; P < 0.0001). Another
study by Goldgar DE et al. [35] in 2011 analyzed 15 dif-
ferent A-T families and revealed that pathogenic
V2424G variant accompanied with increased risk of
breast cancer with a relative risk of 8 (95% CI: 2.3–27.4;
P = 0.0005. In addition, another study by Southey MC
et al. [30] in 2016 reported that V2424G missense vari-
ant was detected in 12 of 42,671 patients suffered from
invasive breast cancer and one of 42,164 normal control
population that these statistics results in an OR of 11.0
(95% CI:1.42–85.7; p = 0.0012). Also, Mitui M et al. [36]
evaluated the clinical consequences of ATM gene alter-
ations using stable transfection and among the 12 mis-
sense variants examined, ATM V2424G variant was one
of the variants which were associated with an increased
risk of cancer.
The meta-analysis on the adjusted case-control studies
revealed that ATM D1853V missense variant has the
least association with an increased risk of breast cancer.
Gao LB et al. [37] in 2010 revealed that there is signifi-
cantly no relationship between the D1853V missense
variant and the risk of breast cancer development [37]
that this finding is congruent with our results.
Another objective of our study was to investigate the
association of ATM variants with breast cancer in differ-
ent regions. Although the incidence of breast cancer is
higher in the Americas and Europe than in the Asian
continent [38, 39], it is interesting to note that the asso-
ciation between ATM variants and breast cancer is
Fig. 2 The forest plot of Association between ATM and Breast Cancer in Adjusted Case Control Studies (Adjusted Odds Ratio)
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greater in Asian countries than in American and Euro-
pean countries in all three sub-groups analyses that is
probably due to racial differences, environmental condi-
tions, patterns of life and the effects of other genes or
specific haplotype combinations in that region [39].
The overall risk heterogeneity in our study was
67.4, which could be due to the way we measured,
sample-sizes designs, inclusion criteria, family his-
tory and BRCA1/2 mutation status and could dis-
tort the interpretation of our results, so we
performed a sub-group analysis based on variant
type, region and heterozygosity to illustrate this
heterogeneous factor and thus reduced the hetero-
geneity up to zero.
Table 3 Summary odds ratio (OR) or relative risk (RR) Estimates [95% confidence intervals (CIs)] for observational studies conducted







Between studies Between subgroups
I2 P heterogeneity z Q P heterogeneity
Adjusted Case Control studies
Heterozygosity variants
Hetro 13 1.98 (1.22–3.19) 80% 0.0001 2.78 5.03 0.0001
Hemo 4 1.63 (1.20–2.22) 0.0% 0.929 2.12
Hetro/Hemo 7 1.22 (1.01–1.46) 0.0% 0.433 3.14
Continent
Asia 2 4.21 (0.78–22.88) 89.5% 0.0001 1.67 4.03 0.0001
America 3 1.55 (1.19–2.01) 60.4% 0.001 3.22
European 2 1.24 (0.94–1.64) 18.5% 0.297 1.49
Type
c.7271 T > G 2 8.94 (4.28–18.67) 0.0% 0.789 5.83
D1853V 2 0.43 (0.09–2.07) 78.6% 0.031 1.05
S707P 3 1.17 (0.73–1.87) 49.2% 0.140 0.66 4.03 0.0001
F858L 2 1.43 (1.02–2.00) 0.0% 0.943 2.10
IVS38–8 T > C, c.5557G > A 2 1.90 (0.80–4.48) 48.9% 0.162 1.46
IVS38–8 T > C 2 3.04 (1.48–6.25) 0.0% 0.963 3.04
IVS24-9delT 2 1.70 (1.13–2.57) 0.0% 0.922 2.54
5557G > A 3 1.33 (0.89–1.99) 54.7% 0.110 1.39
IVS24-9delT, IVS38–8 T > C, 2 1.90 (0.80–4.48) 48.9% 0.162 1.46
5557G > A 2 1.90 (0.80–4.48) 48.9% 0.162 1.46
IVS24-9delT, IVS38–8 T > C
Unadjusted Case Control studies
Heterozygosity variants
Hetro 28 1.31 (1.05–1.64) 76.3% 0.0001 2.35 3.89 0.001
Hetro/Hemo 3 3.43 (0.99–11.84) 90.9% 0.0001 1.95
Continent
Asia 3 5.37 (1.66–17.48) 86.5% 0.0001 2.79
America 2 1.58 (1.07–2.33) 67.8% 0.0001 2.32 3.89 0.0001
European 4 1.08 (0.85–1.38) 74.8% 0.0001 0.63
Type
c.1066–6 T > G 8 1.69 (0.91–3.14) 78.1% 0.0001 1.67
Ser49Cys 3 9.24 (4.78–17.87) 0.0% 0.468 6.61
7271 T > G (V2424G) 2 27.97 (5.01–35.07) 62% 0.105 3.80 3.89 0.0001
IVS38–8 T > C 6 1.22 (0.98–1.51) 0.0% 0.874 1.78
D1853N 6 1.22 (0.98–1.51) 58.9% 0.032 0.67
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Limitation
Since the primary studies used in this meta-analysis did
not provide sufficient information about the exact age of
the patients, the type of breast cancer, its stage and
grade, the hereditary or sporadic type and unilateral or
bilateral breast cancer, further subgroup analysis was not
possible. Furthermore, there are few cohort studies in
this area, and we need more studies.
Conclusion
This meta-analysis shows that the pathogenic ATM vari-
ants are associated with an increased risk of breast can-
cer. Accordingly, ATM variants, including V2424G have
the highest risk of breast cancer incidence while ATM
D1853V, L546V, and S707P variants have the least im-
pact on breast cancer incidence.
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